Sym-023 is under clinical development by Symphogen and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData, Phase I drugs for Bile Duct Cancer (Cholangiocarcinoma) have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Sym-023’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Sym-023 overview

Sym-023 is under development for the treatment of advanced/ unresectable or metastatic solid tumor malignancies and lymphomas, bile duct cancer (cholangiocarcinoma), advanced or metastatic esophageal squamous cell carcinoma, metastatic biliary tract carcinoma including adenocarcinoma of the intra- and/or extra-hepatic bile ducts and gallbladder carcinoma. It is administered through intravenous route. It is a recombinant, fully human monoclonal antibody (mAb). The drug candidate acts by targeting TIM-3. It is developed based on sympress platform technology.

It was under development for the treatment of small-cell lung cancer, cholangiocarcinoma, small-cell lung cancer, urothelial cell cancer, endometrial cancer.

Symphogen overview

Symphogen is a biopharmaceutical company that specializes in the field of recombinant antibody mixtures for therapeutic use in cancer. The company focuses on developing superior monoclonal antibody (mAb) mixture therapeutics. The product pipeline provides novel approaches to a wide range of cancer types including metastatic colorectal cancer (mCRC), solid tumor malignancies, and lung cancer. It has collaborations for the development of antibody therapeutics in immuno-oncology with the Shire and infectious disease area with Genentech. The company has offices in Denmark and New Jersey, the US. Symphogen is headquartered in Ballerup, Denmark.

For a complete picture of Sym-023’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.